Loading clinical trials...

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE2

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of Type 2 Diabetes for at least 3 months.
•Diabetes managed with diet and exercise alone or with either metformin or sulfonylurea alone as an adjunct to diet and exercise.
•Diabetes therapy must be unchanged for at least 3 months prior to screening.
•Females must be of non-childbearing potential (surgically sterilized or at least 1 year post-menopausal, as defined by cessation of menses). Female patients who are not surgically sterilized and who are less than or equal to 45 years should have their post-menopausal status confirmed by FSH greater that 30ng/mL at screening.

Exclusion Criteria

•Current use of insulin or any antidiabetic agent other than a sulfonylurea agent or metformin.
•Current use of metformin or a sulfonylurea agent in combination.
•History of liver disease.
•History of unstable angina (as defined by the Braunwald system), myocardial infarction, or a coronary revascularization procedure within the past 6 months.
•Currently suspected carcinoma or history of carcinoma in the last 5 years, with the exception of excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin.

Locations (42)

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Birmingham, Alabama, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Huntsville, Alabama, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Peoria, Arizona, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Tucson, Arizona, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Little Rock, Arkansas, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Bakersfield, California, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Pico Rivera, California, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

San Diego, California, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Santa Ana, California, United States

For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)

Denver, Colorado, United States

Key Dates

Last Updated

July 19, 2006

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

naveglitazar

DRUG

Sponsors

Lead Sponsor

Eli Lilly and Company

Related Studies

Technology Intensified Diabetes Education Study in African Americans

NCT02088658

Diabetes Mellitus, Type 2Diabetes Mellitus, Adult-Onset+3 more

COMPLETEDPHASE1

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163

Diabetes Mellitus, Non-Insulin-DependentHypertriglyceridemia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions